Combination drug therapy demonstrates potential to treat AMD subtype
Data from patients with a subtype of AMD enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ...
Tag: megan baldwin
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met ...
Opthea progresses DME trials despite COVID-19 disruption
Results are imminent in biopharmaceutical company Opthea’s latest clinical trial evaluating the safety and efficacy of its lead drug candidate ...